Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons

This study has been completed.
Valeant Canada Limited
Information provided by:
University of Manitoba Identifier:
First received: February 14, 2008
Last updated: February 25, 2008
Last verified: June 2007

Objectives: To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in people with spinal cord injury (SCI).

Methods: Twelve subjects were enrolled in this double-blind, placebo-controlled, crossover study. They received either nabilone or placebo during the first four-week period (0.5mg OD with option to increase to 0.5mg BID), then outcome measures were assessed. After a two-week washout, subjects were crossed-over to the opposite arm.

The primary outcome was the Ashworth scale for spasticity in the most involved muscle group, chosen by the subject and clinician. The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change .

Condition Intervention Phase
Spasticity in Spinal Cord Injured Persons
Drug: nabilone then placebo
Drug: placebo then nabilone
Phase 2

Study Type: Interventional
Official Title: Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study

Resource links provided by NLM:

Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Ashworth scale in most involved group muscles [ Time Frame: 10 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change . [ Time Frame: 10 weeks ] [ Designated as safety issue: Yes ]

Study Start Date: July 2007
Study Completion Date: December 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
first on treatment then on Placebo
Drug: nabilone then placebo
The subjects were first on Nabilone, then crossed over to placebo
Placebo Comparator: 2
first on placebo then on treatment
Drug: placebo then nabilone
the subjects were first on placebo then crossed over to nabilone


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with spinal cord injury were eligible for the study if they are 18-65 years old, have C5 (ASIA A-D) and below and the injury occurred greater than 1 year previously. They had to have stable neurological level of injury with moderate spasticity (Ashworth >/= 3) and no cognitive impairments. The spasticity medications needed to be unchanged for at least 30 days before inclusion, and no botulinum toxin injections for > 4 months.

Exclusion Criteria:

They were excluded if they had:

  • Heart disease as cannabinoids can reduce heart rate and blood pressure
  • History of psychotic disorders, schizophrenia or any active psychological disorder
  • Previously documented sensitivity to marijuana or other cannabinoid agents
  • Severe liver dysfunction
  • Cognitive impairment
  • Major illness in another body area
  • If they were pregnant or nursing mother
  • Had history of drug dependency
  • Used smoked cannabis < 30 days before the onset of the study or were unwilling not to smoke during the study; OR
  • If they fixed tendon contractures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00623376

Canada, Manitoba
Rehabilitation hospital ,800 sherbrook St.
Winnipeg, Manitoba, Canada, R3A 1M4
Sponsors and Collaborators
University of Manitoba
Valeant Canada Limited
  More Information

No publications provided

Responsible Party: Sepideh Pooyania, University of Manitoba Identifier: NCT00623376     History of Changes
Other Study ID Numbers: 4940
Study First Received: February 14, 2008
Last Updated: February 25, 2008
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Muscle Spasticity
Muscle Hypertonia
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Signs and Symptoms
Anti-Anxiety Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Gastrointestinal Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on February 27, 2015